IV Lidocaine Infusion for Neuropathic Pain

Key facts

Sponsor

Henry Ford Health System

Principal Investigator

NABIL SIBAI, M.D.

HENRY FORD HEALTH SYSTEMS

Eligibility

18 years · All sexes

Timeline

2016 – 2023

Study locations (1)

• Henry Ford Health Systems, Detroit, Michigan, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Complex regional pain syndrome type 1

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNCT07364266
  Analgesic Amputation for Algodystrophy: Feedback From a Case Series
  University Hospital, Brest
• ACTIVE NOT RECRUITINGNANCT07037069
  Effectiveness of DT vs GMIT on Wrist Pain and Function in Patients With Reflex Sympathetic Dystrophy
  Superior University
• RECRUITINGNANCT06769373
  The Effects of Whirlpool and Contrast Bath in Patients with Complex Regional Pain Syndrome After Distal Radius Fracture
  Afyonkarahisar Health Sciences University
• RECRUITINGPHASE1NCT06393101
  The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome
  University of California, San Diego
• ENROLLING BY INVITATIONPHASE4NCT06306157
  Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
  Hospital for Special Surgery, New York
• RECRUITINGNANCT04767646
  Evaluation of the Relationship Between the Duration of the Evolution of the Complex Regional Pain Syndrome Type 1 (CRPS 1) and Effectiveness of the Continuous Peripheral Nerve Block (CPNB) Associated With an Intensive Rehabilitation Program
  Pôle Saint Hélier
• RECRUITINGNANCT02502162
  Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
  Stanford University

See all trials for Complex regional pain syndrome type 1 →